MX367389B - Compuestos y sus metodos de empleo. - Google Patents

Compuestos y sus metodos de empleo.

Info

Publication number
MX367389B
MX367389B MX2015006493A MX2015006493A MX367389B MX 367389 B MX367389 B MX 367389B MX 2015006493 A MX2015006493 A MX 2015006493A MX 2015006493 A MX2015006493 A MX 2015006493A MX 367389 B MX367389 B MX 367389B
Authority
MX
Mexico
Prior art keywords
compounds
methods
glutaminase
formula
pharmaceutical compositions
Prior art date
Application number
MX2015006493A
Other languages
English (en)
Other versions
MX2015006493A (es
Inventor
M Lemieux Rene
G Salituro Francesco
Popovici-Muller Janeta
O Saunders Jeffrey
Chen Yongsheng
M Travins Jeremy
Original Assignee
Agios Pharmaceuticals Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc Star filed Critical Agios Pharmaceuticals Inc Star
Publication of MX2015006493A publication Critical patent/MX2015006493A/es
Publication of MX367389B publication Critical patent/MX367389B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente también se describen métodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
MX2015006493A 2012-11-22 2013-11-21 Compuestos y sus metodos de empleo. MX367389B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (2)

Publication Number Publication Date
MX2015006493A MX2015006493A (es) 2015-08-05
MX367389B true MX367389B (es) 2019-08-19

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006493A MX367389B (es) 2012-11-22 2013-11-21 Compuestos y sus metodos de empleo.

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP3456719A1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN108727307A (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA030646B1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG10201609940RA (es)
SI (1) SI2922850T1 (es)
SM (1) SMT201800504T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TW201906825A (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CA2897333C (en) 2013-01-15 2021-07-06 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
CN111892589A (zh) * 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use
CR20160497A (es) * 2014-04-30 2016-12-20 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
SI3164394T1 (sl) 2014-07-03 2020-08-31 Board Of Regents, The University Of Texas System GLS1 inhibitorji za zdravljenje bolezni
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004359A1 (en) 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
CN108602782B (zh) 2015-12-22 2022-06-17 德克萨斯大学系统董事会 N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
US10278968B2 (en) * 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN111225903B (zh) 2017-10-18 2024-08-16 德州大学系统董事会 谷氨酰胺酶抑制剂疗法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019232403A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020191356A1 (en) * 2019-03-21 2020-09-24 Goncalves Marcus Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
DK0691962T3 (da) 1993-03-29 2000-10-16 Basf Ag 1-amino-3-phenoxypropanderivater som modulatorer ved multilægemiddelresistens
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ES2215957T3 (es) 2002-08-01 2004-10-16 Mtm Laboratories Ag Metodo para diagnostico basado en una solucion.
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP1861715B1 (en) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
US8563695B2 (en) 2007-11-19 2013-10-22 Genentech, Inc. Antibodies that bind β2
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2812457T3 (es) 2010-06-23 2021-03-17 Univ Louisville Res Found Inc Uso de ácidos grasos en procedimientos para detectar cáncer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
JP2015514062A (ja) 2012-03-15 2015-05-18 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US20160008380A1 (en) 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CN111892589A (zh) 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use

Also Published As

Publication number Publication date
HRP20181628T1 (hr) 2018-12-14
AU2018202954A1 (en) 2018-05-17
EP2922850B1 (en) 2018-07-18
CN104936954A (zh) 2015-09-23
US20190084976A1 (en) 2019-03-21
CA2893510A1 (en) 2014-05-30
PH12017502141A1 (en) 2019-02-27
AU2013347771B2 (en) 2018-02-01
RS57859B1 (sr) 2018-12-31
WO2014079011A1 (en) 2014-05-30
IL238958B (en) 2019-09-26
IL238958A0 (en) 2015-07-30
JP6333277B2 (ja) 2018-05-30
EA201890754A1 (ru) 2018-08-31
SI2922850T1 (sl) 2018-10-30
JP2016500082A (ja) 2016-01-07
PH12015501150A1 (en) 2015-08-17
US10689375B2 (en) 2020-06-23
PH12015501150B1 (en) 2018-05-04
PE20151072A1 (es) 2015-08-26
HUE040111T2 (hu) 2019-02-28
EP2922850A4 (en) 2016-05-18
EA030646B1 (ru) 2018-09-28
DK2922850T3 (en) 2018-10-08
NZ708382A (en) 2020-04-24
ES2690390T3 (es) 2018-11-20
AR093598A1 (es) 2015-06-10
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
US20150291576A1 (en) 2015-10-15
CY1120581T1 (el) 2019-07-10
CA2893510C (en) 2021-01-19
TW201427963A (zh) 2014-07-16
ECSP15026557A (es) 2016-01-29
AU2013347771A1 (en) 2015-06-11
EP2922850A1 (en) 2015-09-30
TW201906825A (zh) 2019-02-16
CN104936954B (zh) 2018-08-14
TWI629268B (zh) 2018-07-11
SMT201800504T1 (it) 2018-11-09
MY177344A (en) 2020-09-13
SA515360469B1 (ar) 2017-07-11
EA201590987A1 (ru) 2015-12-30
CL2015001392A1 (es) 2016-04-22
JP2018150316A (ja) 2018-09-27
HK1214593A1 (en) 2016-07-29
LT2922850T (lt) 2018-09-10
TR201812360T4 (tr) 2018-09-21
WO2014079136A1 (en) 2014-05-30
SG11201504049VA (en) 2015-07-30
SG10201609940RA (en) 2016-12-29
UA117360C2 (uk) 2018-07-25
BR112015011830A2 (pt) 2017-07-11
PL2922850T3 (pl) 2018-12-31
CR20150316A (es) 2015-08-28
PT2922850T (pt) 2018-10-15
CN108727307A (zh) 2018-11-02
EP3456719A1 (en) 2019-03-20
WO2014079150A1 (en) 2014-05-30
US10087172B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
MY199894A (en) Prmt5 inhibitors and uses thereof
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
IN2014KN02601A (es)
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12016501462A1 (en) Neprilysin inhibitors
PH12015501038A1 (en) Inhibitors of iap
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX356102B (es) Compuestos y métodos para tratar leucemia.
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1

Legal Events

Date Code Title Description
FG Grant or registration